4.8 Article

Topoisomerases facilitate transcription of long genes linked to autism

Journal

NATURE
Volume 501, Issue 7465, Pages 58-+

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nature12504

Keywords

-

Funding

  1. NICHD NIH HHS [P30 HD003110, T32 HD040127, P30HD03110, R01HD068730, R01 HD068730, T32HD040127] Funding Source: Medline
  2. NIGMS NIH HHS [R01GM101974, R01 GM101974] Funding Source: Medline
  3. NIMH NIH HHS [R01 MH093372, R01MH093372] Funding Source: Medline
  4. NINDS NIH HHS [P30NS045892, P30 NS045892] Funding Source: Medline

Ask authors/readers for more resources

Topoisomerases are expressed throughout the developing and adult brain and are mutated in some individuals with autism spectrum disorder (ASD). However, how topoisomerases are mechanistically connected to ASD is unknown. Here we find that topotecan, a topoisomerase 1 (TOP1) inhibitor, dose-dependently reduces the expression of extremely long genes in mouse and human neurons, including nearly all genes that are longer than 200 kilobases. Expression of long genes is also reduced after knockdown of Top1 or Top2b in neurons, highlighting that both enzymes are required for full expression of long genes. By mapping RNA polymerase II density genome-wide in neurons, we found that this length-dependent effect on gene expression was due to impaired transcription elongation. Interestingly, many high-confidence ASD candidate genes are exceptionally long and were reduced in expression after TOP1 inhibition. Our findings suggest that chemicals and genetic mutations that impair topoisomerases could commonly contribute to ASD and other neurodevelopmental disorders.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available